From rxpgnews.com
Gamma Secretase Modulator Program Announced for Alzheimer's disease
By Cellzome Inc.,
May 24, 2005 - 10:26:38 AM
Cellzome Inc. today announced that Ortho-McNeil Pharmaceutical, Inc. has exercised its option to license and develop Cellzome's Gamma Secretase Modulator (GSM) program, under the terms of their March 2005 collaboration agreement. The program includes identifying new medicines for the treatment of Alzheimer's disease.
Under the terms of the collaboration, Cellzome will receive an additional technology access fee and continued research funding to deliver clinical drug candidates to Ortho-McNeil Pharmaceutical. Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), an affiliate of Ortho-McNeil Pharmaceutical, will supply research support for the discovery research that will be conducted at Cellzome.
Tim Edwards, Cellzome's CEO, said: "I am delighted that Ortho-McNeil Pharmaceutical has exercised its option over the Cellzome GSM project. In collaboration with J&JPRD, we are working towards identifying clinical candidates, to be tested as potential treatments for this devastating disease."
Under the terms of the collaboration, Cellzome provides access to its existing Alzheimer's disease program technology, including insights into its Amyloid Precursor Protein (APP) processing pathway map and new drug targets. Cellzome's chemical proteomics technology and lead optimisation capability along with J&JPRD's pharmaceutical research capability will be applied to identify additional compounds Ortho-McNeil Pharmaceutical had an option to license Cellzome's Gamma Secretase Modulator program, which includes novel small molecules for development as orally active treatments. J&JPRD will provide research support for the discovery research that will be conducted at Cellzome. Ortho-McNeil Pharmaceutical will be responsible for development, manufacturing and commercialisation of drugs that result from the collaboration.
All rights reserved by RxPG Medical Solutions Private Limited ( www.rxpgnews.com )